Posters Featured in this Tour:

PT2: Comparison of Prescription Drug Affordability Boards across the United States

PT4: Will the Ira's Negotiation Timelines Delay Access to Drugs for Orphan Indications?

PT5: Impacts of National Drug Price Negotiation on Type 2 Diabetes Drugs Price, Volume and Spending in China

PT9: Evaluating Healthcare Costs and Demographics of Medicare Part D Beneficiaries Impacted By First Top 10 Drugs Selected for Price Negotiations Under the Inflation Reduction Act (IRA)

PT10: Utility of the ISPOR Presentations Database to Support the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation (DPN): An Apixaban and Rivaroxaban Case Study

PT11: Impact of the Inflation Reduction Act on Payer Utilization Management – Insights from a Quantitative Survey